雷夫·约翰森：中国已成为大力推动创新药引进的国家

视频加载中，请稍候...

自动播放

play 你好中国第二期：雷夫 约翰逊

向前 向后

　　新浪财经讯 在2019中国发展高层论坛特别策划《你好，中国》节目中，阿斯利康董事长雷夫·约翰森指出，中国已成为世界上大力推动创新药物引进的国家之一，中国的药品市场准入和审批上市的时间已经大大缩短，这意义重大。

　　他表示，中国的大部分人都将从良好的医疗系统中获益。在这样的大背景下，阿斯利康也希望能成为推动更健全的健康医疗计划的一份子。

　　以下为对话实录：

　　Question：When did you start participating in CDF， and what has impressed you most during your journey in CDF？

　　问：您是什么时候开始参与中国发展高层论坛（CDF）的？在您参与CDF的这段过程中，令您印象最深刻的是什么？

　　Answer：I’ve been participating in the CDF for many years now， and I really came into CDF because I wanted to know how policy was shaping in China， and how China was developing as a business person．

　　答：我参加中国发展高层论坛已经很多年了。而此次我来中国实地参与CDF的原因是我想要从一名商业人士的角度去了解中国的政策是如何制定的，以及中国是如何发展的。

　　What has impressed me most I think is that over this fairly long 10 years that I’ve been able to participate， I’ve seen the forum come into a very strong dialogue and discussion mode， where obviously I have learned a lot from the Chinese side， but I’ve also been asked to participate in panels， and in another way， so that interactivities in such way that I felt I could also in some small way contribute to the development of forum．

　　令我印象最深的是，在我参与的这不短的十年历程中，我有幸见证了中国发展高层论坛逐步形成了一种非常热烈的对话与探讨的模式。得益于此，我从中国方面获益良多。与此同时，我也被邀请参加圆桌讨论，以另一种互动方式，为论坛的发展贡献一丝绵薄之力。

　　So， all in all， I think this combination of really understanding coming from the outside – what goes on in China， how policy is formed， and then at the same time， in some small manners perhaps， but still pleasant to experience a listening atmosphere to what we from the outside can say．

　　所以，总的来说，我认为中国发展高层论坛能够帮助外界去真正地理解中国——包括中国经历了什么，政策如何形成；与此同时，论坛还打造了一种友善的倾听氛围，让我们这些来自外界的人士得以表达见解。

　　Question：What are the changes towards CDF and development of China within the past 20 years that provide highlight？

　　问：过去20年有哪些变化为CDF和中国发展带来了亮点？

　　Answer：CDF， I think， has changed with China， and to some extent also perhaps helped China to change．

　　答：我认为CDF既随中国一起改变，也在一定程度上帮助中国做出改变。

　　With the opened-up and reformed agenda that was put into China， and the development of that over the many decades that I can actually cover， it’s easy to see that there is a lot of learning and a lot of initiatives that have been needed to explore the opportunities as China to access the rightful place in the world economy．

　　随着中国改革开放的深入，以及过去数十年来我能明显感受到的中国的发展，不难看出：当中国在世界经济中渐入佳境时，我们需要大量的经验和举措去探索其中的机遇。

　　I think the forum CDF has been very much a central part of having the rest of the world understand how that is forming； but I think it’s also been very important to reflect， as we do in China Development Forum， to reflect what the outside world’s expectations are．

　　我认为很大程度上，CDF论坛在让世界其他地区了解中国进程上起到了非常关键的作用；同时，正如我们在中国高层发展论坛所做的那样，反映外部世界的期望也非常重要。

　　I think what I’m most impressed with has been this real holding-on， stay-in-the-course that China has done over the past many decades， and especially so perhaps in the last couple of years．

　　我印象最深刻的是在过去的几十年，尤其是最近几年中中国所展现出的这种坚持，贯彻始终的行事风格。

　　We have seen the Belt and Road Initiative； we have seen a lot of focus on science and technology development， we have seen a lot of wanting from China to participate in the global context， in the global business， but also in global society around us．

　　我们见证了“一带一路”倡议；看到中国政府对于科学技术发展的大量投入，同时，我们还看到对中国对于进一步融入全球化背景，参与到全球商业以及国际社会中的期望。

　　I think the ability to continue to do that in such way that everyone around China， as China develops into the rightful place in the world economy， everyone around China should also feel that they too are winners．

　　我认为，随着中国在世界经济中发展到应有的地位，中国有能力继续这样做，让每一个中国人都感到自己也是发展的赢家。

　　Real globalization， real global trade， and real participation in the overall concept of how the world develops， means that everyone in China， but obviously also everyone outside of China should feel that they are winners in that whole configuration of how the world should look like．

　　在世界发展的总体概念中，真正的全球化、真正的国际贸易、真正的国际参与意味着中国内外的每个人都应该觉得他们是整个世界格局下的赢家。

　　Question：At this point， what kind of challenges does your company or your industry faces in China？ What kind of suggestions do you have for China’s future development？

　　问：在这个节点上，您的公司或者您所处的行业在中国面临哪些挑战？您对中国的未来发展有哪些建议？

　　Answer：In the pharmaceuticals industry， obviously we are part of an innovative industry where we try to get innovative medicines to patients as quickly as it’s ever possible．

　　答：很显然，我们身处的制药行业也属于创新行业的一部分；在这个行业中，我们希望能够尽可能快地为患者带来创新药物。

　　I’m much impressed with the fact that the access and the approval periods in China for medicines coming have been reduced in such way that is meaningfully so that China is one of the quicker countries to send innovative medicines into．

　　令我印象深刻的是，中国的药品市场准入和审批上市的时间已经大大缩短，这意义重大。中国已成为世界上大力推动创新药物引进的国家之一。

　　In the greater context， we in the pharmaceuticals industry and we AstraZeneca want to be part of the greater healthcare program．

　　在这样的大背景下，阿斯利康希望能成为推动更健全的健康医疗计划的一份子。

　　Obviously， a big part of the population in China will have the ability to be part of a good healthcare system - a reasonable healthcare system as we say sometimes in China．

　　显然，中国的大部分人都将从良好的医疗系统中获益，在中国，我们偶尔称之为合理的医疗系统。

　　There will be a need for a less silo thinking than there present is．

　　这要求在现有的基础上减少各自为政的“谷仓”思维方式。

　　There isn’t really a drug budget， a hospital budget， or a pretreatment or prevention budget． There is actually all of that coming together in a patient-centric way．

　　这将不会再有药物预算、医院预算、预处理或预防预算的分割。这一切都将紧紧围绕着“以患者为中心”的价值观。

　　So if we think about the development in China， ourselves included， if we can do that in a patient-centric way， such that the best we can prevent the disease， then treat it， and hopefully also making the treatment at the absolute lowest cost to the benefit of patients， but also to the benefit of the society in terms of the cost and the opportunities to get people back into productive work at the quickest．

　　所以，如果我们能用“以患者为中心”的思维去考虑中国的未来发展，包括我们自己未来在中国的发展，我们就能更好地预防和治疗疾病，以最低的治疗成本惠及患者，同时也将造福于社会，从治疗成本与治愈机会两个层面上帮助人们尽快重新投入到高效工作中。

　　All of that comes together into what I would call a healthcare cluster， and everything we can do to help to provide that cluster with good data， we have digital data， we have innovation around digital data， such that we probably began to see medicines coming out of data， and not necessarily only out of the clinic．

　　这些元素的结合就形成了我所说的医疗集群，而我们所能做的一切都有助于为这个集群提供良好的数据。我们有数据，有围绕数据的创新，这样，我们或许会开始看到药物可以由数据驱动，而不仅仅来自于临床。

　　All of that is an area where we in the pharmaceuticals industry would like to participate， we AstraZeneca would like to participate， while we also see great opportunities for China and the citizens of China．

　　与数据创新有关的一切都是我们制药行业包括阿斯利康在内愿意涉猎的领域，同时我们也看到了中国和中国人民的巨大机遇。

　　新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。

责任编辑：谢长杉